Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

Recruiting now · Phase 2

Conditions studied: Advanced Breast Cancer

In brief

A study to investigate camizestrant in combination with atirmociclib in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.

Key facts

Study ID

NCT07427394

Run by

AstraZeneca

People needed

24

Starts

2026-05-06

Expected to finish

2027-12-29

Last updated by the study team

2026-08-07

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Research Site — St Louis, Missouri, United States (enrolling)
• Research Site — Nashville, Tennessee, United States (enrolling)
• Research Site — Cambridge, United Kingdom (enrolling)
• Research Site — London, United Kingdom (enrolling)
• Research Site — Manchester, United Kingdom (enrolling)
• Research Site — East Providence, Rhode Island, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.